Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Liabilities and Shareholders Equity: 2021-2024

Historic Liabilities and Shareholders Equity for Prime Medicine (PRME) over the last 4 years, with Dec 2024 value amounting to $297.5 million.

  • Prime Medicine's Liabilities and Shareholders Equity rose 15.69% to $385.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 17.49%. This contributed to the annual value of $297.5 million for FY2024, which is 53.47% up from last year.
  • As of FY2024, Prime Medicine's Liabilities and Shareholders Equity stood at $297.5 million, which was up 53.47% from $193.9 million recorded in FY2023.
  • In the past 5 years, Prime Medicine's Liabilities and Shareholders Equity registered a high of $360.3 million during FY2022, and its lowest value of $193.9 million during FY2023.
  • In the last 3 years, Prime Medicine's Liabilities and Shareholders Equity had a median value of $297.5 million in 2024 and averaged $283.9 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first crashed by 46.20% in 2023, then skyrocketed by 53.47% in 2024.
  • Prime Medicine's Liabilities and Shareholders Equity (Yearly) stood at $301.9 million in 2021, then climbed by 19.37% to $360.3 million in 2022, then plummeted by 46.20% to $193.9 million in 2023, then spiked by 53.47% to $297.5 million in 2024.